Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104874 | 0.85 | PPARG (0.43) | MAOBMAOAADRB2CYP3A4 | |
| SCHEMBL15679980 | 0.84 | SRR (0.53) | MAOBMAOASRRSLC7A5 | |
| SCHEMBL757308 | 0.84 | SRR (0.53) | MAOBMAOASRRSLC7A5 | |
| SCHEMBL1094835 | 0.84 | SRR (0.53) | MAOBMAOASRRSLC7A5 | |
| SCHEMBL1094834 | 0.84 | SRR (0.53) | MAOBMAOASRRSLC7A5 | |
| SCHEMBL21443824 | 0.81 | MAOB (0.42) | MAOBMAOAADRB2CYP19A1TAAR1 | |
| SCHEMBL1104884 | 0.80 | SRR (0.39) | MAOBMAOACYP19A1SRRALDH1A1 | |
| SCHEMBL9263675 | 0.78 | MAOB (0.48) | MAOBMAOAADRB2CYP19A1TAAR1 | |
| SCHEMBL1104873 | 0.77 | MAOB (0.48) | MAOBMAOAADRB2CYP19A1ALDH1A1 | |
| SCHEMBL17070188 | 0.75 | NPSR1 (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-9913817-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2018-03-13 | — | — | US | disclosed |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LTD (IE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2018-03-08 | — | — | US | disclosed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | disclosed |
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2017-03-02 | — | — | US | disclosed |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | NOGRA PHARMA LIMITED (IE) | 2015-09-24 | — | — | US | disclosed |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LIMITED (IE) | 2015-09-10 | — | — | US | disclosed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | disclosed |
| US-8501806-B2 | Methods for preventing or reducing colon carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2013-08-06 | — | — | US | disclosed |
| US-8153693-B2 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease | GIULIANI INTERNATIONAL LIMITED (IE) | 2012-04-10 | — | — | US | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056349-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | MAOB 250/4885MAOA 359/4885ADRB2 2702/4885 |
| US-20180065921-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | MAOB 950/4885MAOA 1738/4885ADRB2 2296/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | MAOB 950/4885MAOA 1738/4885ADRB2 2296/4885 |
| US-20110288058-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NQO1, NFE2L2, CYBB | MAOB 250/4885MAOA 359/4885ADRB2 2702/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MAOB 2825/4885MAOA 3500/4885ADRB2 337/4885 |
| US-20150250749-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | MAOB 1200/4885MAOA 1183/4885ADRB2 2078/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | MAOB 1290/4885MAOA 1478/4885ADRB2 4332/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | MAOB 2770/4885MAOA 3519/4885ADRB2 223/4885 |
| US-20150265514-A1 | METHODS OF INHIBITING HAIR GROWTH | DCX, HDGF, MKI67 | MAOB 276/4885MAOA 247/4885ADRB2 4048/4885 |
| US-20180064667-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | MAOB 2825/4885MAOA 3500/4885ADRB2 337/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | MAOB 3944/4885MAOA 3577/4885ADRB2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.